finance
Analysts Initiate Coverage on Palantir Technologies and Sutro Biopharma with Outperform Ratings
Two Wall Street analysts have started coverage on Palantir Technologies and Sutro Biopharma, assigning Outperform ratings and specific price targets. The initiations were reported on April 30, 2026. Shares of both companies closed lower than their respective targets on the previous day.
BenzingaAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Wall Street analysts initiated coverage on two companies, providing ratings and price targets. Mizuho analyst Salim Syed began coverage of Sutro Biopharma Inc with an Outperform rating and a price target of $50. The company's shares closed at $35.39 on Wednesday.
Oppenheimer analyst Param Singh initiated coverage on Palantir Technologies Inc with an Outperform rating and a price target of $200. Palantir shares closed at $137.97 on Wednesday. These initiations reflect analysts' views on the potential performance of the stocks. For additional analyst rating changes, including upgrades and downgrades, Benzinga provides a comprehensive page.
The announcements come amid ongoing market activity, with other stocks like Centene Corp, Crane Co, and T-Mobile US Inc showing price movements. However, the focus remains on the new coverage for Sutro Biopharma and Palantir Technologies.
